This commercial-stage biotechnology company developing next-generation, targeted antibody drug conjugates is aiming to achieve double-digit year-over-year revenue growth for its lead drug.
The company we are profiling today is ADC Therapeutics SA (ADCT) and the drug in focus is Zynlonta.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.